PAI
AKTX

Palo Alto Investors’s Akari Therapeutics AKTX Stock Holding History

Palo Alto Investors’s Portfolio AKTX Stock Details AKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3,651
Closed -$42.2K – 52
2025
Q4 		$42.2K Hold
3,651
– – 0.01% 49
2025
Q3 		$147K Hold
3,651
– – 0.03% 43
2025
Q2 		$171K Hold
3,651
– – 0.04% 44
2025
Q1 		$181K Hold
3,651
– – 0.03% 42
2024
Q4 		$178K Buy
+3,651
New +$275K 0.03% 42

Other funds holding AKTX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
CAM
Cresset Asset Management Chicago, Illinois $23.1B AUM 27.04% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TC
Truvestments Capital Sarasota, Florida $554M AUM 32.49% 1-Year Est. Return

Palo Alto Investors's AKTX Position: Q1 2026 in Review

Palo Alto Investors sold out of Akari Therapeutics (AKTX) in Q1 2026, closing a stake of 3,651 shares — an estimated $42.2K sold.

Palo Alto Investors first reported a position in AKTX in Q4 2024 and held it in 5 quarters. The position peaked at $181K in Q1 2025. 6 funds tracked by Wall St. Rank hold AKTX as of Q1 2026.

  • Palo Alto Investors reported no remaining Akari Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Palo Alto Investors sold 3,651 Akari Therapeutics shares in Q1 2026, an estimated $42.2K.
  • Palo Alto Investors first reported a position in Akari Therapeutics in Q4 2024 and held it in 5 quarters.
  • Palo Alto Investors's Akari Therapeutics position peaked at $181K in Q1 2025.
  • 6 funds tracked by Wall St. Rank held Akari Therapeutics as of Q1 2026.

Based on Palo Alto Investors's 13F filing for Q1 2026, filed 15 May 2026.